Apexigen
NASDAQ:APGNApexigen, Inc., a clinical-stage biopharmaceutical company, discovers and develops antibody therapeutics for oncology. It develops a pipeline of product candidates, including APX005M, a humanized agonist antibody that is in Phase II clinical development for the treatment of solid tumors, such as melanoma, esophageal and gastroesophageal junction, sarcoma, and ovarian cancers in combination with immunotherapy, chemotherapy, radiation therapy, and cancer vaccines; and APX601, a humanized antagonist antibody that is in Phase I/II clinical trial for the treatment of multiple tumor indications, as well as APX801, an NK cell engager to activate natural killer cells to killing of tumor cells. Apexigen, Inc. was founded in 2010 and is headquartered in San Carlos, California.
Direxion Moonshot Innovators ETF
NYSEARCA:MOONThe Direxion Moonshot Innovators ETF (MOON) is an exchange-traded fund that is based on the S&P Kensho Moonshots index. The fund tracks a tier-weighted index that selects US-listed companies seeking innovative technologies. MOON was launched on Nov 12, 2020 and is managed by Direxion.